이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
SpringWorks Therapeutics 관리
관리 기준 확인 2/4
SpringWorks Therapeutics' CEO는 Saqib Islam, Jul2018 에 임명되었습니다 의 임기는 5.92 년입니다. 총 연간 보상은 $ 18.35M, 4% 로 구성됩니다. 4% 급여 및 96% 보너스(회사 주식 및 옵션 포함). 는 $ 26.88M 가치에 해당하는 회사 주식의 1% 직접 소유합니다. 26.88M. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 5.4 년입니다.
주요 정보
Saqib Islam
최고 경영자
US$18.4m
총 보상
| CEO 급여 비율 | 4.0% |
| CEO 임기 | 5.9yrs |
| CEO 소유권 | 1.0% |
| 경영진 평균 재임 기간 | 4yrs |
| 이사 회 평균 재임 기간 | 5.4yrs |
최근 관리 업데이트
Recent updates
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06SpringWorks Therapeutics announces C-level promotions
Dec 15CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
보상 대 시장: Saqib 의 총 보상 ($USD 18.35M )은 US 시장( $USD 6.80M ).
보상과 수익: 회사가 수익성이 없는 동안 Saqib 의 보상이 증가했습니다.
CEO
Saqib Islam (54 yo)
5.9yrs
테뉴어
US$18,351,489
보상
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 5.9yrs | US$18.35m | 1% $ 28.0m | |
| Chief Financial Officer | 4.8yrs | US$3.74m | 0.025% $ 703.9k | |
| Chief Operating Officer | 3.4yrs | US$6.64m | 0.24% $ 6.6m | |
| Chief Medical Officer | 2.9yrs | US$4.31m | 0.032% $ 894.7k | |
| Chief Accounting Officer | 4.3yrs | 데이터 없음 | 0.0083% $ 232.0k | |
| Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Communications & Investor Relations | 6.4yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel & Secretary | 4.4yrs | US$2.83m | 0.018% $ 513.5k | |
| Chief People Officer | 3.8yrs | US$2.52m | 0.0065% $ 182.1k | |
| Chief Commercial Officer | 3.3yrs | US$4.94m | 0.014% $ 386.6k |
4.0yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: SWTX 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 5.9yrs | US$18.35m | 1% $ 28.0m | |
| Independent Director | 4.8yrs | US$520.14k | 0.014% $ 398.3k | |
| Independent Chairman of the Board | 8.4yrs | US$545.14k | 0.41% $ 11.4m | |
| Independent Director | 6.8yrs | US$508.45k | 0.014% $ 398.3k | |
| Independent Director | 1.9yrs | US$507.64k | 0.011% $ 301.5k | |
| Independent Director | 4.1yrs | US$520.14k | 0% $ 0 |
5.4yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: SWTX 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.